ARTES and Rhein Minapharm continue their successful product development collaboration

Lan­gen­feld and Cairo – ARTES Biotech­nol­o­gy and Rhein Minapharm Bio­genet­ics joint­ly announced the suc­cess­ful pro­duc­tion of a new tar­get of a ther­a­peu­tic pro­tein. This is the first result of a long-term research col­lab­o­ra­tion that was signed in Jan­u­ary 2008. Con­se­quent­ly, the two com­pa­nies extend­ed their col­lab­o­ra­tion in May 2009.

ARTES applied its pro­pri­etary Hansenu­la tech­nol­o­gy plat­form and know-how to the gen­er­a­tion of a ther­a­peu­tic pro­tein cho­sen by Rhein Minapharm that is typ­i­cal­ly pro­duced in E coli. Rhein Minapharms´s new tar­get is now pro­duced from the Hansenu­la plat­form at con­sid­er­able high­er yields and at reduced costs com­pared to alter­na­tive bac­te­r­i­al or yeast systems.

Under the terms of agree­ment ARTES hand­ed over the pro­duc­tion cell lines and received anoth­er mile­stone pay­ment. Addi­tion­al­ly, ARTES and Rhein Minapharm extend­ed their col­lab­o­ra­tion aim­ing at addi­tion­al tar­gets for Minapharm´s port­fo­lio. ARTES will be respon­si­ble for the gen­er­a­tion of new pro­duc­tion cell lines and will share the process research and devel­op­ment respon­si­bil­i­ty with Minapharm.

Our long-term agree­ment is an impor­tant mile­stone in the exist­ing rela­tion­ship between our com­pa­nies and we are real­ly proud that our strain and process devel­op­ment work enables Rhein Minapharm to devel­op their inno­v­a­tive tar­get pipeline and to save pro­duc­tion costs,” said Dr. Michael Pio­ntek, founder and Man­ag­ing Direc­tor of ARTES.

Dr. Wafik Bardis­si, Chair­man and CEO of Minapharm added:
“Togeth­er with ARTES, we are cre­at­ing a cross-func­tion­al R&D team­work to fur­ther endow our pipeline with afford­abil­i­ty and inno­va­tion, char­ac­ter­is­tic of Hansenu­la derived pro­teins already in clin­i­cal prac­tice and key mar­ket dri­vers of our emerg­ing markets.”